We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Laps the Stock Market: Here's Why
Read MoreHide Full Article
In the latest close session, Adma Biologics (ADMA - Free Report) was up +1.22% at $9.95. The stock's performance was ahead of the S&P 500's daily gain of 0.62%. Elsewhere, the Dow gained 0.58%, while the tech-heavy Nasdaq added 0.83%.
The infectious disease drug developer's stock has dropped by 37.27% in the past month, falling short of the Medical sector's loss of 3.18% and the S&P 500's gain of 0.8%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.96 per share and a revenue of $639.74 million, representing changes of +60% and +25.4%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Adma Biologics currently has a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Adma Biologics is currently trading at a Forward P/E ratio of 10.29. This indicates a discount in contrast to its industry's Forward P/E of 20.64.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Laps the Stock Market: Here's Why
In the latest close session, Adma Biologics (ADMA - Free Report) was up +1.22% at $9.95. The stock's performance was ahead of the S&P 500's daily gain of 0.62%. Elsewhere, the Dow gained 0.58%, while the tech-heavy Nasdaq added 0.83%.
The infectious disease drug developer's stock has dropped by 37.27% in the past month, falling short of the Medical sector's loss of 3.18% and the S&P 500's gain of 0.8%.
Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.96 per share and a revenue of $639.74 million, representing changes of +60% and +25.4%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Adma Biologics currently has a Zacks Rank of #1 (Strong Buy).
In terms of valuation, Adma Biologics is currently trading at a Forward P/E ratio of 10.29. This indicates a discount in contrast to its industry's Forward P/E of 20.64.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.